Arcus Biosciences Clinical Trials

Company details

Status: Public
HQ: 3928 Point Eden Way, Hayward, California 94545, US
Founded: 2015
Employees: 655
Programs: 53
Drugs: 25
Patents: 30

Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

Arcus Biosciences pipeline update: casdatifan, quemliclustat, domvanalimab Jun 8, 2026

View all news & analysis →

Recent trial activity

8 updates

Latest clinical program signals indexed for Arcus Biosciences.

Trial registry

59 studies

2022-503071-28-00
ARC-10

Phase 3 active small_molecule

Squamous Non-small cell Lung Cancer, Non-Small Cell Lung Cancer, Non squamous Non Small Cell Lung Cancer, Lung Cancer

CTIS ↗
2023-507522-16-00
STAR-221

Phase 3 active small_molecule

Metastatic Esophageal or Gastric Cancer, Esophageal or Gastric Cancer

CTIS ↗
2024-511116-25-00
ARC-12

Phase 1 active other

Multiple Myeloma, Diffuse large B cell lymphoma (DLBCL), Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Melanoma, Advanced Solid Tumor, Gastrointestinal (GI) cancer, Hematological (heme) cancer, Gynecological (Gyn) cancer, Non-small cell lung cancer (NSCLC), Non-Hodgkin Lymphoma, Gastric Cancer, Cervical Cancer

CTIS ↗
2024-511158-36-00
ARC-9

Phase 2 active small_molecule

Metastatic colorectal cancer

CTIS ↗
2024-511917-40-00
ARC-21(EDGE-Gastric)

Phase 2 active small_molecule

Upper Gastrointestinal Tract Cancer, Advanced Upper Gastrointestinal Tract Malignancies, Gastrointestinal Tract Malignancies

CTIS ↗
2024-513317-12-00
PRISM-1

Phase 3 active small_molecule

Pancreatic cancer, Metastatic Pancreatic ductal adenocarcinoma (mPDAC), Pancreatic ductal adenocarcinoma (PDAC)

CTIS ↗
2024-515023-11-00
PEAK-1

Phase 3 active small_molecule

Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma

CTIS ↗
2024-519142-70-00
ARC-20

Phase 1 active other

Solid Tumors, Clear Cell Renal Cell Carcinoma

CTIS ↗
NCT03628677
Domvanalimab

Phase 1 completed small_molecule

Solid Tumor, Unspecified, Adult

CT.gov ↗
NCT03629756
Etrumadenant

Phase 1 completed small_molecule

Non-small Cell Lung Cancer

CT.gov ↗
NCT03677973
AB680

Phase 1 completed small_molecule

Healthy Volunteers

CT.gov ↗
NCT03719326
Etrumadenant

Phase 1 completed small_molecule

TNBC - Triple-Negative Breast Cancer

CT.gov ↗
NCT03720678
etrumadenant

Phase 1 completed small_molecule

GastroEsophageal Cancer

CT.gov ↗
NCT03821246
Atezolizumab

Phase 2 active small_molecule

Prostate Adenocarcinoma

CT.gov ↗
NCT03846310
Etrumadenant

Phase 1 completed small_molecule

Non Small Cell Lung Cancer Metastatic

CT.gov ↗
NCT04087018
zimberelimab

Phase 1 completed small_molecule

Advanced Solid Tumors

CT.gov ↗
NCT04104672
AB680

Phase 1 active small_molecule

Advanced Pancreatic Cancer

CT.gov ↗
NCT04262856
Domvanalimab

Phase 2 active small_molecule

Non Small Cell Lung Cancer

CT.gov ↗
NCT04381832
Etrumadenant

Phase 2 completed small_molecule

Prostatic Neoplasms, Castration-Resistant

CT.gov ↗
NCT04575311
AB680

Phase 1 completed small_molecule

Healthy Volunteers

CT.gov ↗
NCT04656535
Zimberelimab

Phase 1 active small_molecule

Glioblastoma

CT.gov ↗
NCT04660812
AB680

Phase 2 completed small_molecule

Metastatic Colorectal Cancer

CT.gov ↗
NCT04736173
Domvanalimab

Phase 2 active small_molecule

Non Small Cell Lung Cancer

CT.gov ↗
NCT04772989
AB308

Phase 1 completed small_molecule

Advanced Solid Tumor

CT.gov ↗
NCT04791839
Zimberelimab

Phase 3 active small_molecule

Non-small Cell Lung Cancer

CT.gov ↗
NCT04892875
Zimberelimab

Phase 1 terminated small_molecule

Head and Neck Cancer

CT.gov ↗
NCT05024097
Etrumadenant (AB928)

Phase 2 active small_molecule

Rectal Cancer

CT.gov ↗
NCT05117554
Casdatifan

Phase 1 completed small_molecule

Healthy Participants

CT.gov ↗
NCT05130177
Zimberelimab

Phase 2 active small_molecule

Melanoma

CT.gov ↗
NCT05154136
Etrumadenant

Phase 1 completed small_molecule

Healthy Participants

CT.gov ↗
NCT05177770
SRF617

Phase 2 terminated small_molecule

Metastatic Castration-resistant Prostate Cancer

CT.gov ↗
NCT05211895
Durvalumab

Phase 3 active small_molecule

Non-Small Cell Lung Cancer

CT.gov ↗
NCT05277012
Etrumadenant

Phase 1 completed small_molecule

Healthy Participants

CT.gov ↗
NCT05329766
Domvanalimab

Phase 2 active small_molecule

Gastrointestinal Tract Malignancies

CT.gov ↗
NCT05411146
[14C]-etrumadenant

Phase 1 completed small_molecule

Healthy Participants

CT.gov ↗
NCT05419479
ZIMBERELIMAB

Phase 2 on hold small_molecule

Pancreatic Cancer

CT.gov ↗
NCT05502237
Zimberelimab

Phase 3 active small_molecule

Non-small Cell Lung Cancer

CT.gov ↗
NCT05536141
casdatifan

Phase 1 active small_molecule

Clear Cell Renal Cell Carcinoma

CT.gov ↗
NCT05568095
Domvanalimab

Phase 3 active small_molecule

Advanced Upper Gastrointestinal Tract Adenocarcinoma

CT.gov ↗
NCT05633667
Zimberelimab (ZIM)

Phase 2 active small_molecule

Lung Cancer

CT.gov ↗
NCT05676931
Domvanalimab

Phase 2 active small_molecule

Advanced Non-Small Cell Lung Cancer

CT.gov ↗
NCT05688215
Fluorouracil

Phase 2 active small_molecule

Borderline Resectable Pancreatic Adenocarcinoma

CT.gov ↗
NCT05724563
Zimberelimab

Phase 2 active small_molecule

Hepatobiliary Cancer

CT.gov ↗
NCT05891171
AB598

Phase 1 active small_molecule

Advanced Cancer

CT.gov ↗
NCT05915442
Quemliclustat

Phase 2 active small_molecule

Oligometastatic Prostate Cancer

CT.gov ↗
NCT05999513
Casdatifan

Phase 1 completed small_molecule

Healthy Participants

CT.gov ↗
NCT06004921
AB801

Phase 1 completed small_molecule

Cancer

CT.gov ↗
NCT06048133
Gemcitabine

Phase 2 active small_molecule

Biliary Tract Carcinoma

CT.gov ↗
NCT06048484
Zimberelimab

Phase 2 active small_molecule

Pancreatic Ductal Adenocarcinoma

CT.gov ↗
NCT06120075
AB801

Phase 1 active small_molecule

Advanced Cancer

CT.gov ↗
NCT06191796
zanzalintinib

Phase 1 terminated small_molecule

Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors

CT.gov ↗
NCT06608927
Quemliclustat

Phase 3 active small_molecule

Metastatic Pancreatic Ductal Adenocarcinoma

CT.gov ↗
NCT06727565
Domvanalimab

Phase 2 active small_molecule

Head and Neck Squamous Cell Carcinoma

CT.gov ↗
NCT06919991
Casdatifan

Phase 1 completed small_molecule

Healthy Participants

CT.gov ↗
NCT07000149
Volrustomig

Phase 3 active small_molecule

Advanced Clear Cell Renal Cell Carcinoma

CT.gov ↗
NCT07011719
Casdatifan

Phase 3 active small_molecule

Metastatic Clear Cell Renal Cell Carcinoma

CT.gov ↗
NCT07283848
Zimberelimab

Phase 2 terminated small_molecule

Adenocarcinoma Stomach

CT.gov ↗
NCT07364214
Quemliclustat

Phase 1 completed small_molecule

Healthy Participants

CT.gov ↗
NCT07397611
Casdatifan

Phase 2 active small_molecule

Renal Cell Carcinoma

CT.gov ↗

Recent trial activity

Trial registry

Stay Ahead in Pharma